Award recognises and rewards journalism that extends public awareness and understanding of COPD

Boehringer IngelheimThe independent judging panel of the Eloquium Award has today named three journalists as winners of the 2007 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD) the fastest growing cause of death in the world's most advanced economies. Currently, 600 million people live with COPD which is projected to become the world’s third-leading cause of death by 2020.[1,2]

The Boehringer Ingelheim Communication Award - Eloquium - attracted submissions from 13 countries, including Brazil, Chile, China, Ecuador, England, Japan, Lebanon, Sweden and Venezuela. Entries were judged by an independent panel of global COPD experts and leading journalists.*

The three winning entries of the Eloquium Award are:

  • 1st: Annu Likkanen, Veteranen, Two cigarettes were Ulla-Britt's Undoing (Sweden)
  • 2nd: Gilson Monteiro, Rádio Eldorado, Unknown enemy (Brazil)
  • 3rd: María de los Ángeles González Izurieta, Vea, Tobacco is consuming you (Chile)

"It is important that patients seek early diagnosis and treatment for COPD and key to this is improving education and awareness about the disease," commented Professor Klaus Rabe, Chair of the Judging panel and Chairman of Pulmonology, Department of Pulmonology at Academisch Ziekenhuis Leiden, The Netherlands. "While COPD is beginning to build a warranted presence in the media, a continued and sustained presence is still needed."

Commenting on the winning entry, Patricia Reaney of ReutersHealth said, "By focusing on one woman's battle with COPD the author of the winning article showed how smoking causes the illness, its impact on a person's life and the importance of early detection and treatment to limit further lung damage."

About chronic obstructive pulmonary disease (COPD)
COPD is a progressive respiratory disease that causes significant deterioration of lung function resulting in breathlessness, activity limitation and disability associated with the disease.[3] Early diagnosis and treatment can greatly improve quality of life for COPD patients, yet many are unaware they even have the disease.[4] It has been estimated that up to 50% of Americans and 75% of Europeans with COPD are undiagnosed.[4,5]

About Eloquium
Eloquium is a communication award that is sponsored by Boehringer Ingelheim. It has been awarded to three winners each year, since its launch in 2003.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more infomration, visit www.boehringer-ingelheim.com.

References:
[1] Murray CJL, Lopez AD. eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge; Harvard University Press; 1996.
[2] World Health Organization. World Health Report 2004. Statistical Annex. Annex table 2 and 3: 120-131.
[3] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. National Institute of Health; 2005. Available at http://www.goldcopd.com.
[4] Rudolf M. The reality of drug use in COPD: The European Perspective. Chest 2000; 117:29S-32S 5 Centers for Disease Control and Prevention. Surveillance Summaries, August 2, 2002. MMWR 2002:51 (No SS-6);1.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]